Related Experiment Video
Updated: Dec 9, 2025
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors
Souvik Banerjee1, Derek D Norman2, Shanshan Deng3
1Department of Physical Sciences, University of Arkansas Fort Smith, Fort Smith, AR 72913, USA; Department of Physiology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA; Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Abstract:
The lysophospholipase D autotaxin (ATX) generates lysophosphatidic acid (LPA) that activates six cognate G-protein coupled receptors (GPCR) in cancerous cells, promoting their motility and invasion. Four novel compounds were generated aided by molecular docking guided design and synthesis techniques to obtain new dual inhibitors of ATX and the lysophosphatidic acid receptor subtype 1 (LPAR1). Biological evaluation of these compounds revealed two compounds, 10 and 11, as new ATX enzyme inhibitors with potencies in the range of 218-220 nM and water solubility (>100 µg/mL), but with no LPAR1 inhibitory activity. A QSAR model was generated that included four newly designed compounds and twenty-one additional compounds that we have reported previously. The QSAR model provided excellent predictability of the pharmacological activity and potency among structurally related drug candidates. This model will be highly useful in guiding the synthesis of new ATX inhibitors in the future.
Insights
Researchers developed novel dual inhibitors targeting autotaxin (ATX) and lysophosphatidic acid receptor 1 (LPAR1) to combat cancer cell invasion. Two compounds effectively inhibited ATX, showing promise for future drug development.
Area of Science:
- Medicinal Chemistry
- Oncology
- Biochemistry
Background:
- Autotaxin (ATX) generates lysophosphatidic acid (LPA), which drives cancer cell motility and invasion via G-protein coupled receptors (GPCRs).
- Targeting ATX and its receptors is a promising strategy for cancer therapy.
Purpose of the Study:
- To design and synthesize novel dual inhibitors of autotaxin (ATX) and lysophosphatidic acid receptor 1 (LPAR1).
- To evaluate the inhibitory activity and drug-like properties of newly synthesized compounds.
Main Methods:
- Molecular docking guided design and synthesis of novel compounds.
- Biological evaluation including enzyme inhibition assays and assessment of water solubility.
- Quantitative Structure-Activity Relationship (QSAR) modeling.
Main Results:
- Two novel compounds, 10 and 11, were identified as potent autotaxin (ATX) enzyme inhibitors (218-220 nM).
- These compounds exhibited good water solubility (>100 µg/mL).
- No inhibitory activity against lysophosphatidic acid receptor 1 (LPAR1) was observed for these compounds.
Conclusions:
- Compounds 10 and 11 represent new, potent, and soluble ATX inhibitors.
- A QSAR model was developed, demonstrating excellent predictability for future ATX inhibitor drug design.
- This work provides a foundation for developing novel cancer therapeutics targeting the ATX pathway.
More Related Videos
05:08Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
Published on: July 8, 2025
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
